MA39927A - Inhibiteurs de glyt1 pour le traitement de troubles hématologiques - Google Patents
Inhibiteurs de glyt1 pour le traitement de troubles hématologiquesInfo
- Publication number
- MA39927A MA39927A MA039927A MA39927A MA39927A MA 39927 A MA39927 A MA 39927A MA 039927 A MA039927 A MA 039927A MA 39927 A MA39927 A MA 39927A MA 39927 A MA39927 A MA 39927A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- blood disorders
- glyt1 inhibitors
- glyt1
- inhibitors
- Prior art date
Links
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14166497 | 2014-04-30 | ||
| PCT/EP2015/059037 WO2015165842A1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 destinés à être utilisés dans le traitement de troubles hématologiques |
| EP15717916.9A EP3137073B1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39927A true MA39927A (fr) | 2017-03-08 |
| MA39927B1 MA39927B1 (fr) | 2018-09-28 |
Family
ID=50677958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39927A MA39927B1 (fr) | 2014-04-30 | 2015-04-27 | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9877963B2 (fr) |
| EP (1) | EP3137073B1 (fr) |
| JP (1) | JP6283766B2 (fr) |
| KR (1) | KR101869185B1 (fr) |
| CN (1) | CN106163520B (fr) |
| AR (1) | AR100209A1 (fr) |
| CY (1) | CY1120508T1 (fr) |
| ES (1) | ES2683184T3 (fr) |
| HR (1) | HRP20181205T1 (fr) |
| MA (1) | MA39927B1 (fr) |
| MY (1) | MY189930A (fr) |
| PH (1) | PH12016501784A1 (fr) |
| PT (1) | PT3137073T (fr) |
| RS (1) | RS57535B1 (fr) |
| SG (2) | SG11201608397UA (fr) |
| SI (1) | SI3137073T1 (fr) |
| TR (1) | TR201809598T4 (fr) |
| WO (1) | WO2015165842A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3199156A1 (fr) * | 2016-02-01 | 2017-08-02 | Heinrich-Heine-Universität Düsseldorf | Utilisation d'antagonistes du transporteur de la glycine 1 comme analgésiques du systeme nerveux central |
| CU20200106A7 (es) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| IL305803A (en) * | 2021-03-12 | 2023-11-01 | Disc Medicine Inc | Compounds and methods for the treatment of anemia associated with a ribosomal disorder |
| WO2022241274A1 (fr) * | 2021-05-14 | 2022-11-17 | Disc Medicine, Inc. | Méthodes de traitement de protoporphyrie érythropoïétique, de protoporphyrie liée à l'x ou de porphyrie érythropoïétique congénitale avec des inhibiteurs de transport de glycine |
| US20240390362A1 (en) * | 2021-05-27 | 2024-11-28 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
| CA3257064A1 (fr) * | 2022-05-31 | 2023-12-07 | Disc Medicine, Inc. | Compositions et méthodes de traitement de la porphyrie hépatique avec des inhibiteurs de transport de glycine |
| WO2025059425A1 (fr) * | 2023-09-15 | 2025-03-20 | Disc Medicine, Inc. | Inhibiteurs de glyt-1 et leurs utilisations |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004263306B2 (en) * | 2003-08-11 | 2010-04-22 | F. Hoffmann-La Roche Ag | Piperazine with or-substituted phenyl group and their use as GLYT1 inhibitors |
| CN101119968B (zh) * | 2005-02-07 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 作为甘氨酸转运蛋白1抑制剂的杂环取代的苯基甲酮衍生物 |
-
2015
- 2015-04-27 MY MYPI2016001545A patent/MY189930A/en unknown
- 2015-04-27 EP EP15717916.9A patent/EP3137073B1/fr active Active
- 2015-04-27 SG SG11201608397UA patent/SG11201608397UA/en unknown
- 2015-04-27 KR KR1020167030222A patent/KR101869185B1/ko active Active
- 2015-04-27 SG SG10201909382U patent/SG10201909382UA/en unknown
- 2015-04-27 TR TR2018/09598T patent/TR201809598T4/tr unknown
- 2015-04-27 JP JP2017505724A patent/JP6283766B2/ja active Active
- 2015-04-27 CN CN201580016721.4A patent/CN106163520B/zh active Active
- 2015-04-27 ES ES15717916.9T patent/ES2683184T3/es active Active
- 2015-04-27 PT PT157179169T patent/PT3137073T/pt unknown
- 2015-04-27 WO PCT/EP2015/059037 patent/WO2015165842A1/fr not_active Ceased
- 2015-04-27 RS RS20180897A patent/RS57535B1/sr unknown
- 2015-04-27 MA MA39927A patent/MA39927B1/fr unknown
- 2015-04-27 SI SI201530334T patent/SI3137073T1/sl unknown
- 2015-04-27 HR HRP20181205TT patent/HRP20181205T1/hr unknown
- 2015-04-28 AR ARP150101268A patent/AR100209A1/es not_active Application Discontinuation
-
2016
- 2016-09-13 PH PH12016501784A patent/PH12016501784A1/en unknown
- 2016-10-26 US US15/334,722 patent/US9877963B2/en active Active
-
2018
- 2018-08-06 CY CY20181100809T patent/CY1120508T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3137073A1 (fr) | 2017-03-08 |
| AR100209A1 (es) | 2016-09-21 |
| KR20160130517A (ko) | 2016-11-11 |
| ES2683184T3 (es) | 2018-09-25 |
| PT3137073T (pt) | 2018-07-27 |
| CN106163520A (zh) | 2016-11-23 |
| US20170042888A1 (en) | 2017-02-16 |
| SG10201909382UA (en) | 2019-11-28 |
| US9877963B2 (en) | 2018-01-30 |
| JP6283766B2 (ja) | 2018-02-21 |
| EP3137073B1 (fr) | 2018-06-06 |
| RS57535B1 (sr) | 2018-10-31 |
| TR201809598T4 (tr) | 2018-07-23 |
| CY1120508T1 (el) | 2019-07-10 |
| SG11201608397UA (en) | 2016-11-29 |
| CN106163520B (zh) | 2019-12-13 |
| PH12016501784B1 (en) | 2016-11-07 |
| MA39927B1 (fr) | 2018-09-28 |
| HRP20181205T1 (hr) | 2018-09-21 |
| KR101869185B1 (ko) | 2018-06-19 |
| PH12016501784A1 (en) | 2016-11-07 |
| MY189930A (en) | 2022-03-22 |
| WO2015165842A1 (fr) | 2015-11-05 |
| JP2017511385A (ja) | 2017-04-20 |
| SI3137073T1 (sl) | 2018-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1034I2 (fr) | Composés aryle, hétéroaryle et hétérocycliques pour le traitement de troubles induits par un complément | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3481387A4 (fr) | Methodes et compositions pour le traitement de troubles épileptiques | |
| EP3370703A4 (fr) | Combinaison de gemcabène pour le traitement de maladies cardiovasculaires | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| EP3328376A4 (fr) | Méthodes et compositions pour le traitement de troubles de la reprogrammation métabolique | |
| EP3374502A4 (fr) | Procédés pour le traitement de dystrophies cornéennes | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| EP3448398A4 (fr) | Compositions et méthodes pour le traitement de troubles cutanés | |
| EP3313325A4 (fr) | Échafaudages implantables pour le traitement de la sinusite | |
| MA39753A (fr) | Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues | |
| PT3119397T (pt) | Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama | |
| EP3351189A4 (fr) | Instrument de traitement pour endoscope | |
| EP3288592A4 (fr) | Utilisation de cannabidiol pour le traitement de spasmes infantiles | |
| MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
| EP3362065A4 (fr) | Polythérapie pour le traitement de malignités | |
| EP3335041A4 (fr) | Biomarqueurs pour le traitement de la pelade | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| EP3316887A4 (fr) | Inhibiteurs de gls1 pour le traitement de maladies | |
| MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
| EP3334432A4 (fr) | Cerdulatinib pour le traitement du myélome | |
| EP3621434A4 (fr) | Méthodes de traitement de troubles neuropsychiatriques | |
| EP3318205A4 (fr) | Instrument de traitement pour endoscope | |
| EP2825173A4 (fr) | Inhibiteurs de calmoduline pour le traitement de troubles ribosomiques et de ribosomapathies |